Capricor Therapeutics Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Capricor Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Capricor Therapeutics stock.
View analyst ratings for Capricor Therapeutics or view top-rated stocks.

Wall Street analysts have given Capricor Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Capricor Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Capricor Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 17th 2021.
View our earnings forecast for Capricor Therapeutics.

Capricor Therapeutics Inc (NASDAQ:CAPR) posted its earnings results on Thursday, November, 12th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by $0.02. The biotechnology company had revenue of $0.02 million for the quarter. Capricor Therapeutics had a negative trailing twelve-month return on equity of 55.79% and a negative net margin of 2,304.84%.
View Capricor Therapeutics' earnings history.

Capricor Therapeutics' stock was trading at $1.0050 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CAPR stock has increased by 510.9% and is now trading at $6.14.
View which stocks have been most impacted by COVID-19.

2 brokers have issued 1-year price objectives for Capricor Therapeutics' stock. Their forecasts range from $9.00 to $12.00. On average, they anticipate Capricor Therapeutics' share price to reach $10.50 in the next year. This suggests a possible upside of 71.0% from the stock's current price.
View analysts' price targets for Capricor Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Capricor Therapeutics include Akebia Therapeutics (AKBA), Magenta Therapeutics (MGTA), Spero Therapeutics (SPRO), Syros Pharmaceuticals (SYRS), Crinetics Pharmaceuticals (CRNX), 89bio (ETNB), SIGA Technologies (SIGA), Avadel Pharmaceuticals (AVDL), Spruce Biosciences (SPRB), Homology Medicines (FIXX), Inozyme Pharma (INZY), Mirum Pharmaceuticals (MIRM), Affimed (AFMD), RAPT Therapeutics (RAPT) and Selecta Biosciences (SELB).
View all of CAPR's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Capricor Therapeutics investors own include Marinus Pharmaceuticals (MRNS), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Inovio Pharmaceuticals (INO), Trevena (TRVN), Dynavax Technologies (DVAX), Chesapeake Energy (CHKAQ), OPKO Health (OPK) and Advanced Micro Devices (AMD).

Capricor Therapeutics trades on the NASDAQ under the ticker symbol "CAPR."

Capricor Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.68%), Northern Trust Corp (0.67%), Bank of New York Mellon Corp (0.44%) and GSA Capital Partners LLP (0.39%).
View institutional ownership trends for Capricor Therapeutics.

CAPR stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp.
View insider buying and selling activity for Capricor Therapeutics or view top insider-selling stocks.

CAPR stock was bought by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Bank of New York Mellon Corp, and BlackRock Inc..
View insider buying and selling activity for Capricor Therapeutics or or view top insider-buying stocks.

Shares of CAPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CAPR stock can currently be purchased for approximately $6.14.

Capricor Therapeutics has a market capitalization of $125.55 million and generates $1 million in revenue each year.

The official website for Capricor Therapeutics is www.capricor.com.

Capricor Therapeutics is headquartered at 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211.

Capricor Therapeutics' mailing address is 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211. The biotechnology company can be reached via phone at 310-358-3200 or via email at [email protected]